APA (7th ed.) Citation

Castro, J. E., Lengerke-Diaz, P. A., Velez Lujan, J., Choi, M. Y., Moreno-Cortes, E. F., Forero, J. V., . . . Kipps, T. J. (2022). Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576. Advances in Hematology, 1. https://doi.org/10.1155/2022/4450824

Chicago Style (17th ed.) Citation

Castro, Januario E., et al. "Ibrutinib Plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions After Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576." Advances in Hematology 2022: 1. https://doi.org/10.1155/2022/4450824.

MLA (9th ed.) Citation

Castro, Januario E., et al. "Ibrutinib Plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions After Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576." Advances in Hematology, 2022, p. 1, https://doi.org/10.1155/2022/4450824.